Answer
For belimumab (Benlysta), decide whether to discontinue breastfeeding or discontinue treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Sources for this answer
- Benlysta 120 mg and 400 mg powder for concentrate for solution for infusionGlaxoSmithKline UK · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 35Document updated
Sources checked